ADVERTISEMENT
regeneron monoclonal antibody sars-cov-2 covid-19 pandemic coronavirus neutralization b.1.351 variant south africa REGN10987 casirivimab and REGN10933 imdevimab
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

drug development, microbiology, immunology

Securing the Antibody Supply Chain through Recombinant Antibody Technology: A COVID-19 Case Study
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 29, 2021 | 1 min read
Nicholas Hutchings will discuss how recombinant antibody technology can speed up the response to a pandemic.
COVID-19 Vaccine Developers Gain Enhanced Access to Supercomputers
Lisa Winter | Mar 27, 2020 | 2 min read
Federal agencies, academic institutions, and industrial partners are joining forces to combat COVID-19 using artificial intelligence.
Clinical Trial Misfortune
Cristina Luiggi | Aug 28, 2012 | 1 min read
A human trial of a hepatitis C treatment is shut down after one of the participants died.
Mining Bacterial Small Molecules
L. Caetano M. Antunes, Julian E. Davies and B. Brett Finlay | Jan 1, 2011 | 10 min read
As much as rainforests or deep-sea vents, the human gut holds rich stores of microbial chemicals that should be mined for their pharmacological potential.
ADVERTISEMENT